.
As eligibility for the COVID-19 vaccine opens up for all Hoosiers, those who identify as white and Asian are taking the lead in getting vaccinated while some minority groups are falling behind.
According to the state’s vaccine dashboard, 6% of available vaccines have been claimed by those who identify as Black in Indiana. Data from the Kaiser Family Foundation shows just 22% of those who are Black have been vaccinated in the state.
While COVID-19 has affected all of the nation regardless of race, Black people are being hospitalized almost three times more than white people, according to the Centers for Disease Control and Prevention.
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
COVID-19 vaccines minus the needle?
By Thomas Curwen - Los Angeles Times
LOS ANGELES With 13 COVID-19 vaccines in use around the world, pharmaceutical companies are exploring second-generation technology that could change how doses are administered and distributed.
These vaccines could be taken orally as a capsule that could be swallowed, as a tablet that dissolves under the tongue or as a nasal spray. Such formulations would not require refrigeration, nor would they need health care workers to administer them.
The efforts are in early stages with no guarantee of success. Research and development costs are steep, and only a small number of companies none with a vaccine currently authorized for use are exploring these alternate methods. The work may seem like a gamble but could play a critical role in ending the pandemic.
Print
With 13 COVID-19 vaccines in use around the world, pharmaceutical companies are exploring second-generation technology that could change how doses are administered and distributed.
These vaccines could be taken orally as a capsule that could be swallowed, as a tablet that dissolves under the tongue or as a nasal spray. Such formulations would not require refrigeration, nor would they need healthcare workers to administer them.
The efforts are in early stages with no guarantee of success. Research and development costs are steep, and only a small number of companies none with a vaccine currently authorized for use are exploring these alternate methods. The work may seem like a gamble but could play a critical role in ending the pandemic.
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.